Charles River Laboratories International, Inc. (CRL)

Several events have influenced Charles River Laboratories International, Inc.'s stock price in the past six months. The company released its Q2 2025 and Q3 2025 earnings, reporting EPS of $1.060 USD and $1.100 USD, respectively. Charles River outlined its 2026 outlook and strategic moves, anticipating organic revenue growth to be at least flat and projecting foreign exchange to add 100–150 basis points to reported revenue growth. The company announced planned acquisitions of K.F. (Cambodia) Ltd. and the remaining 79% of PathoQuest SAS. Analyst sentiment has also impacted the stock, with upgrades from Wall Street Zen and Bank of America, and an increased target price from Barclays. The company currently holds a consensus rating of "Hold" from analysts.

Demand for Charles River Laboratories International, Inc.'s products and services generally exhibits stability within the biopharmaceutical sector. Demand from small and mid-sized biotechnology clients is projected to be stable to slightly improved, and the company has observed improving demand trends in its Discovery and Safety Assessment (DSA) segment throughout the second half of 2025. Overall demand is influenced by the ongoing research and development cycles of its pharmaceutical, biotechnology, and government clients.

Charles River Laboratories International, Inc. is a contract research organization that provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. The company operates within the Pharmaceuticals and Biotechnology sectors, offering services through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. Charles River is recognized as one of the largest CROs globally, particularly for its expertise in toxicology studies, animal research models, and microbial testing services.

Charles River Laboratories International, Inc. has a significant global presence, with operations spanning at least 20 countries. The company maintains facilities across North America, Europe, Asia Pacific, and South America. Key countries with a presence include the United States, Canada, Australia, Belgium, Brazil, China, Finland, France, Germany, Hungary, India, Ireland, Italy, Netherlands, Singapore, South Korea, Spain, Switzerland, and the United Kingdom.

In the past year, Charles River Laboratories has focused on its corporate citizenship and sustainability efforts, publishing its 2023 Corporate Citizenship Report and highlighting progress in ESG areas. The company has also faced public scrutiny and regulatory attention regarding its use of laboratory animals, which can impact its brand reputation.

Charles River Laboratories International, Inc. is predominantly owned by institutional investors, including Vanguard Group Inc., BlackRock, Inc., Wellington Management Group Llp, Allspring Global Investments Holdings, LLC, and State Street Corp. Current and former executives and directors also hold a small single-digit percentage of the company's shares.